Adjuvant chemotherapy in stage I triple-negative breast cancer: A systematic review and meta-analysis of survival outcomes
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: The benefit of adjuvant chemotherapy in patients with surgically-resected, stage-I TNBC remains controversial, especially when tumors are smaller than 10 mm in maximum diameter. We conducted a meta-analysis to evaluate the impact of adjuvant chemotherapy on survival outcomes in this setting, with prespecified subgroup analyses by pathological tumor size (pT1a/b/c). METHODS: > 25%). Small-study effects and robustness were evaluated with Egger's test and influence diagnostics. RESULTS: Twenty-seven studies including 98,499 patients were analysed. Adjuvant chemotherapy resulted in significantly improved OS (HR 0.53, 95%CI 0.42-0.68; p < 0.001) and BCSS (HR 0.70, 95%CI 0.62-0.79; p < 0.001). In pT1a tumors, we found no benefit in terms of OS (HR 0.97, p = 0.91) or BCSS (HR 1.49, p = 0.12). In pT1b disease, chemotherapy use was associated with improved OS (HR 0.68, p < 0.0001), while no BCSS benefit was observed (HR 1.01, p = 0.94); this subgroup analysis should be interpreted cautiously. Finally, in pT1c tumors, adjuvant chemotherapy was associated with improved OS (HR 0.46, p < 0.0001) and BCSS (HR 0.68, p < 0.001). CONCLUSIONS: In surgically-resected stage I TNBC, the association between adjuvant chemotherapy and better survival appears to vary according to tumor-size, with more consistent benefit in patients with tumors > 5 mm and no significant survival advantage observed in pT1a disease. These findings support a tailored, size-based approach, although the OS results should be interpreted cautiously given the observational nature of the evidence and the substantial heterogeneity of the pooled OS analysis.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Adjuvant chemotherapy in stage I triple-negative breast cancer: A systematic review and meta-analysis of survival outcomes
- Date Crossref
- 01/07/2026
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Fondazione IRCCS Istituto Nazionale dei Tumori pays non établi dans la noticeÉtablissement de santé
-
Department of Medical Oncology pays non établi dans la noticeInstitution
-
Unit of Biostatistics for Clinical Research pays non établi dans la noticeÉtablissement de santé
-
The AIRC Institute of Molecular Oncology Department of Medical Oncology pays non établi dans la noticeStructure de recherche
-
University of Milan Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Clinical Trial Center pays non établi dans la noticeÉtablissement de santé
-
Department of Surgery pays non établi dans la noticeInstitution
Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Medical Oncology et Unit of Biostatistics for Clinical Research, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.